ST. LOUIS, Oct. 26 /PRNewswire/ -- The Mattson Jack Group, Inc. (MattsonJack) announces the release of its Comorbidity Database(TM).
Comorbidity Database(TM) is designed to help clients make strategic decisions based on an in-depth understanding of the importance of mutually exclusive and overlapping conditions. Comorbidity Database(TM) consists of two modules: Comorbidity Database(TM) -- CNS 2.0, which focuses on mental health disorders, and Comorbidity Database(TM) -- Med 2.0, which features a broad range of medical diagnoses and risk factors, excluding mental health disorders.
The Comorbidity Database(TM) will provide patient numbers for mutually exclusive segments for any combination of disorders / diagnostic categories. "Pharmaceutical companies can use this information to build accurate market forecasts, identify patient subgroups by various risk factors, and analyze overlaps of subgroup populations," said David Robinson, Director of Epidemiology at MattsonJack.
The Comorbidity Database(TM) product offerings exemplify MattsonJack's commitment to epidemiology and continuous product enhancement. Additional information on disorders or conditions covered by each module, data sources, and additional enhancements can be found on MattsonJack's website: Comorbidity Database(TM). To arrange a personal demonstration of the Comorbidity Database(TM), e-mail Deborah Hammonds, or telephone 314.529.3064.
About The Mattson Jack Group, Inc. (http://www.mattsonjack.com)
Formed in 1986, MattsonJack focuses its client support in three areas of Competency: Business Analytics, Brand Optimization, and Corporate Development services in the pharmaceutical and biotech markets.
MattsonJack's knowledgeware and client productivity tools include Epi
Database(R) and Forecast Architect(R). Additionally, MattsonJack, as one of
the largest global oncology consulting firms, supports its clients' ca
'/>"/>
| SOURCE The Mattson Jack Group, Inc. Copyright©2007 PR Newswire. All rights reserved |